PI3K inhibitors are finally coming of age.
Accepted version
Repository URI
Repository DOI
Change log
Authors
Abstract
Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has been hampered by issues such as poor drug tolerance and drug resistance, several PI3K inhibitors have now received regulatory approval - the PI3Kα isoform-selective inhibitor alpelisib for the treatment of breast cancer and inhibitors mainly aimed at the leukocyte-enriched PI3Kδ in B cell malignancies. In addition to targeting cancer cell-intrinsic PI3K activity, emerging evidence highlights the potential of PI3K inhibitors in cancer immunotherapy. This Review summarizes key discoveries that aid the clinical translation of PI3Kα and PI3Kδ inhibitors, highlighting lessons learnt and future opportunities.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1474-1784
Volume Title
Publisher
Publisher DOI
Rights
Sponsorship
Wellcome Trust (200925/Z/16/Z)
Cancer Research UK (via University College London (UCL)) (548494)
Biotechnology and Biological Sciences Research Council (BB/M013278/1)